Use of infliximab in juvenile onset rheumatological disease associated refractory uveitis: Efficacy in joint and ocular disease
- Srilakshmi M Sharma (s_m_sharma{at}yahoo.com)
- Athimalaipet V Ramanan (athimalaipet.ramanan{at}nbt.nhs.uk)
- Philip Riley (philip.riley{at}nbt.nhs.uk)
Abstract
There is an identified disparity between the efficacy of TNF ( tumor necrosis factor) inhibition in the treatment of uveitis in paediatric onset inflammatory arthritis and that of joint disease (1,2,3,4,5).
We retrospectively reviewed the case notes of 6 patients with aggressive, refractory joint and ocular paediatric- onset disease treated with infliximab in a multi- disciplinary clinic. Our report utilizes the Standardised Uveitis Nomenclature (SUN) grading system (6) for uveitis and steroid dose as an outcome measure. All patients received infliximab infusions at weeks 0, 2, 6 and 8 weekly.








